Literature DB >> 10405779

Lipocortin-1 preserves myocardial responsiveness to beta-adrenergic stimulation in rat papillary muscle.

R H Ritchie1, X Sun, G J Dusting.   

Abstract

1. During septic shock, myocardial contractile dysfunction is accompanied by the release of cytokines and enhanced production of nitric oxide, and the contractile dysfunction is prevented by glucocorticoids. 2. Myocardial dysfunction was induced in vitro by incubation of rat papillary muscle for 15 h with endotoxin (lipopolysaccharide, LPS) and interferon-gamma (IFN-gamma). 3. Both baseline contractile function and inotropic responsiveness to isoprenaline were markedly reduced by the combination of LPS plus IFN-gamma. 4. Lipocortin-1 (LC-1) is induced by glucocorticoids, and LC-1(2-26), its N-terminal fragment, protected the papillary muscle inotropic responsiveness to isoprenaline, but did not affect the decline in baseline contractile function induced by LPS plus IFN-gamma. 5. The mechanisms of this protective action need to be explored further, but LC-1 may prove to be a novel cardioprotective agent for the management of septic shock.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405779     DOI: 10.1046/j.1440-1681.1999.03067.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  2 in total

1.  Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue.

Authors:  James P Warne; Christopher D John; Helen C Christian; John F Morris; Roderick J Flower; David Sugden; Egle Solito; Glenda E Gillies; Julia C Buckingham
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-07-11       Impact factor: 4.310

2.  Annexin-1 peptide Anx-1(2-26) protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemia.

Authors:  Rebecca H Ritchie; Jennifer M Gordon; Owen L Woodman; Anh H Cao; Gregory J Dusting
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.